{"nctId":"NCT00817206","briefTitle":"Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily","startDateStruct":{"date":"2008-12"},"conditions":["Renal Failure"],"count":326,"armGroups":[{"label":"LCP-Tacro","type":"EXPERIMENTAL","interventionNames":["Drug: LCP-Tacro"]},{"label":"Prograf (tacrolimus)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prograf"]}],"interventions":[{"name":"LCP-Tacro","otherNames":["tacrolimus","tacrolimus modified release"]},{"name":"Prograf","otherNames":["tacrolimus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women at least 18 years of age who are recipients of a kidney transplant between 3 months and 5 years before the screening date\n* Patients taking oral Prograf® capsules twice daily, at least 2 mg total dose per day, as part of their maintenance immunosuppression therapy, with tacrolimus trough levels of 5 to 15 ng/mL\n* Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days before receiving study drug\n\nExclusion Criteria:\n\n* Recipients of any transplanted organ other than kidney\n* Recipients of a bone marrow transplant\n* Patients with an eGFR (MDRD7) \\< 30 mL/min at Screening\n* Patients with a spot protein:creatinine ratio \\> 0.5\n* Patients with a WBC count ≤ 2.8 ´ 109/L unless the WBC count has been stable for at least 2 weeks and the absolute neutrophil count is \\> 1.0 ´ 109 /L\n* Patients unable to swallow study medication\n* Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent and who are unwilling or unable to comply with the study protocol requirements\n* Pregnant or nursing women\n* Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception\n* Patients who were treated with any other investigational agent within 3 months before Screening\n* Patients who have taken sirolimus or everolimus within 3 months before Screening\n* Patients on concurrent immunosuppression with MMF (CellCept) or MPS delayed-release tablets (Myfortic) who have not been on stable doses for at least 4 weeks before Screening\n* Patients withdrawn from corticosteroids less than 30 days before Screening\n* Patients with an episode of acute rejection requiring antibody therapy within 3 months before Screening\n* Patients treated for acute rejection within 30 days before Screening\n* Patients who are hepatitis C virus (HCV) negative who have received an HCV positive (HCV RNA by polymerase chain reaction or HCV antibody) donor kidney\n* Patients seropositive for human immunodeficiency virus\n* Patients with a current malignancy or a history of malignancy (within the past 5 years), except basal or nonmetastatic squamous cell carcinoma of the skin that has been treated successfully\n* Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives\n* Patients with severe diarrhea, vomiting, active peptic ulcer, or gastrointestinal disorder that may affect the absorption of tacrolimus\n* Patients with any form of current substance abuse, psychiatric disorder, or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite Endpoint for Efficacy Failure Within 12 Months of Randomization: Death, Graft Failure, Biopsy-proven Acute Rejection or Loss to Follow-up.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":162},"commonTop":["Diarrhoea","Urinary tract infection","Blood creatinine increased","Nasopharyngitis","Upper respiratory tract infection"]}}}